雌、孕激素受体表达在Ⅱ型子宫内膜癌组织中的预后价值

Prognostic value of estrogen and progesterone receptor expression in patients with endometrial typeⅡcarcinoma

目的:探讨雌激素受体(ER)和孕激素受体(PR)状态与子宫内膜癌患者无瘤生存率的关系。方法:共纳入358例子宫内膜癌术后患者,选取患者切除标本,对组织中ER和PR表达的强度和细胞比例进行免疫组化半定量评价,探究其与患者预后的关系。结果:所有患者的平均随访时间为48.2个月(2~60个月),5年内有82例Ⅱ型子宫内膜癌患者复发。ER/PR的表达,无论是强度评分、比例评分还是总评分,都可以很好的预测患者的无瘤生存时间。ER/PR状态总评分是患者无瘤生存的独立影响因素,ER较PR更为显著。对于生存时间,ER高/PR高组患者的无瘤生存时间最长,其次是ER高/PR低组、ER低/PR高组,最低的为ER低/PR低组。结论:在Ⅱ型子宫内膜癌患者中,ER/PR的低表达是无瘤生存的独立危险因素,两者联合检测可以有效对患者的预后进行预测。

Objective:To investigate the relationship between the status of estrogen receptor(ER)and progesterone receptor(PR)and tumor-free survival in patients with endometrial carcinoma.Methods:A total of 358 postoperative patients with endometrial carcinoma were enrolled in this study.The expression intensity and cell proportion of ER and PR in tissues were semi-quantitatively evaluated by immunohistochemistry to explore the relationship between them and the prognosis of the patients.Results:The average follow-up time of all patients was 48.2 months(2~60 months).82 patients with typeⅡendocardial carcinoma recurred within 5 years.The expression of ER/PR,no matter the intensity score,proportional score or total score,can well predict the tumor-free survival time of patients.The total score of ER/PR status was an independent factor affecting tumor-free survival,and ER was more significant than PR.As for the survival time,the tumor-free survival time was the longest in the high ER/PR group,followed by the high ER/low PR group,the low ER/PR high group,and the lowest ER/PR low group.Conclusion:In patients with typeⅡendometrial carcinoma,the low expression of ER/PR is an independent risk factor for tumor-free survival,and the combination of the two can effectively predict the prognosis of patients.